InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana® Thrombectomy Catheter System. The cases were performed across the company’s limited US market release and its European first-in-human study.
“We’ve had the privilege of partnering with some of the most experienced and knowledgeable physicians to reach this important milestone,” said Jeff Elkins, Chief Executive Officer of InterVene, Inc. “We are grateful for their support as we work to deliver purpose-built innovation for difficult-to-treat venous conditions.”
Recana is the first fully integrated mechanical thrombectomy system to receive US Food and Drug Administration (FDA) 510(k) clearance for the treatment of venous in-stent restenosis (ISR) and residual venous obstructions in native veins. The system features a stainless steel, helical debulking catheter, material collection baskets, and introducer and collection sheaths, designed to simplify complex venous procedures and improve clinical outcomes.
ISR and residual venous obstructions develop when a blood clot undergoes structural and composition changes that are resistant to traditional therapies.1 As the vein lumen narrows, blood outflow from the legs is impaired, leading to venous hypertension. This condition is associated with symptoms such as persistent leg swelling, aching pain, skin discoloration, and, in severe cases, venous leg ulcers. In the United States, more than 25 million adults are affected by chronic venous insufficiency caused by venous obstruction, reflux, or both.2
“In-stent restenosis is a common complication following venous stenting,” said Stephen Black, MD, Professor of Surgery, at Guy’s and Thomas’ Hospital, London. “Many of these patients experience debilitating symptoms, but treatment is often limited to conservative care. My experience with Recana has fundamentally changed how I approach this disease.”
“Millions of patients suffer from symptoms related to residual venous obstructions,” said Mark Garcia, MD, FSIR, FACR, Wilmington, DE. “The Recana system shows promise as a new treatment option for native vessel obstructions.”
InterVene is currently conducting a limited US commercial release with select physicians specializing in ISR and residual venous obstructions. The company is also sponsoring prospective clinical studies in Galway, Ireland, led by Gerry O’Sullivan, MD, and London, England, led by Stephen Black, MD.
The first 30 cases included patients having both ISR and native vessel obstructions, many of whom had experienced years of symptoms and multiple prior treatment attempts. InterVene plans to continue its limited market release as it prepares for a broader commercial launch later this year.
About the Recana® Thrombectomy Catheter System
Recana is the first fully integrated system cleared by the FDA for the treatment of venous in-stent restenosis (ISR) and residual native vessel obstructions. The system consists of a stainless steel, helical debulking catheter, material collection baskets, and introducer and collection sheaths. Recana is a purpose-built, standalone platform designed to simplify complex venous procedures and improve clinical outcomes.
About InterVene, Inc.
InterVene is a privately held medical technology company based in Redwood City, California. The company is focused on developing transformative products to treat the long-term complications of venous disease. Its flagship technology, the Recana® Thrombectomy Catheter System, is designed to treat venous in-stent restenosis and residual vein obstructions and occlusions, life-altering conditions that affect millions of people globally. InterVene is backed by RiverVest Venture Partners and Treo Ventures. For more information, visit www.intervene-med.com and connect on LinkedIn.
References
1. Saleem T, Raju S. An overview of in-stent restenosis in iliofemoral venous stents. J Vasc Surg Venous Lymphat Disord. 2022 Mar.
2. Attaran RR, Edwards ML, Arena FJ, et al. 2025 SCAI Clinical Practice Guidelines for the Management of Chronic Venous Disease: This statement was endorsed by the Society for Vascular Medicine (SVM). J Soc Cardiovasc Angiogr Interv. 2025 Jun.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260407271477/en/
Media gallery
